A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Drug: hSTC810 400 mg + PaclitaxelDrug: hSTC810 800 mg + Paclitaxel
- Registration Number
- NCT06016270
- Lead Sponsor
- STCube, Inc.
- Brief Summary
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.
- Detailed Description
The study will be conducted in 2 parts. Phase Ib will evaluate the safety of the combination of hSTC810 with a standard dose of paclitaxel using a 3+3 dose escalation design. Phase II will evaluate the efficacy of hSTC810 + paclitaxel combination therapy using a Simon 2-stage method.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 130
- Ability to understand and sign an informed consent form
- Male or female ≥ 18 years of age
- Histologically or cytologically confirmed SCLC
- R/R ES-SCLC on or after platinum-based chemotherapy for SCLC with documented disease progression
- At least 1 measurable lesion as defined by RECIST 1.1
- Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 or 1
- Life expectancy of at least 3 months
- Adequate organ function as described in the protocol
- For female or male patients with reproductive potential: Agree to use contraception throughout the study and at least 5 months after the last dose.
- Known active leptomeningeal disease (carcinomatous meningitis)
- Known active and uncontrolled central nervous system (CNS) metastases
- Treatment with immunotherapy, chemotherapy, targeted small molecule therapy, or any other investigational agent < 14 days prior to initiation of study treatment
- Treatment with radiation therapy < 14 days prior to initiation of study treatment
- Major surgery < 21 days prior to initiation of study treatment
- Received live vaccine < 30 days prior to initiation of study treatment, including intranasal influenza vaccine
- History of another primary malignancy with protocol-defined exceptions
- Active or history of autoimmune disease requiring systemic treatment
- Receiving high doses of steroids or other immunosuppressive medications
- Active hepatitis B or C infection
- Active or history of non-infectious pneumonitis requiring treatment with steroids
- Active uncontrolled viral, fungal, or bacterial infection including tuberculosis
- Pregnant or breastfeeding female patients
- History of severe hypersensitivity reaction to a monoclonal antibody treatment
- History of severe hypersensitivity reaction or ≥ Grade 3 adverse event (AE) to paclitaxel treatment
- History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to screening
- QT Corrected for Fridericia's method (QTcF) > 470 ms at screening
- Lack of resolution of any toxicity to max Grade 1 (except alopecia)
- Active or history of any condition, therapy, or lab abnormality that may interfere with the patient participation for the full duration of the study
- Known psychiatric or substance use disorder
- Positive Coronavirus disease 2019 (COVID-19) test at screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description hSTC810 400 mg + Paclitaxel hSTC810 400 mg + Paclitaxel hSTC810 400 mg will be administered with a standard dose of paclitaxel hSTC810 800 mg + Paclitaxel hSTC810 800 mg + Paclitaxel hSTC810 800 mg will be administered with a standard dose of paclitaxel
- Primary Outcome Measures
Name Time Method Overall Response Rate (ORR) 3 months Percentage of patients with confirmed Confirmed Response (CR) or Partial Response (PR) as defined by RECIST 1.1 at 3 months
Progression Free Survival (PFS) rate 6 months Proportion of patients without documented progression of disease and alive at 6 months
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) Up to 4 years Time from first dose until the date of objective disease progression or death
Clinical Benefit Rate (CBR) Up to 4 years Percentage of evaluable patients with CR, PR, or Stable Disease (SD) lasting ≥ 24 weeks
Overall Survival (OS) Up to 4 years Time from first dose of study drug until the date of death
Overall Survival (OS) rate 12 months Proportion of patients alive at 12 months after the first dose of study drug
Safety and tolerability Up to 4 years Incidence, causality, and nature of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Overall Response Rate (ORR) Up to 4 years Investigator assessed ORR defined by RECIST 1.1
Duration of Response (DoR) Up to 4 years Time from the date of first documented CR or PR until the date of documented progression or death
Maximum plasma concentration (Cmax) Up to 21 days Maximum plasma concentration of hSTC810 to evaluate PK parameters
Area under the concentration-time curve from 0 to 21 days (AUC0-21) Up to 21 days AUC from 0 to 21 days to evaluate PK parameters
Area under the concentration-time curve extrapolated from 0 to infinity (AUCo-inf) Up to 21 days AUC from time 0 to infinity to evaluate total drug exposure over time
Incidence of anti-drug antibodies (ADA) Up to 4 years Number and percentage of patients with positive ADAs
Trial Locations
- Locations (8)
Seoul National University Bundang Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea St. Vincent's Hospital
🇰🇷Suwon, Korea, Republic of
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Tisch Cancer Institute at Mount Sinai
🇺🇸New York, New York, United States
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of